These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9223568)

  • 1. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
    Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.
    Tsukada J; Tahara A; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Vascul Pharmacol; 2005 Jan; 42(2):47-55. PubMed ID: 15722249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.
    Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    J Cardiovasc Pharmacol; 1997 Dec; 30(6):759-66. PubMed ID: 9436815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
    Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
    Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
    Yatsu T; Tomura Y; Tahara A; Wada K; Tsukada J; Uchida W; Tanaka A; Takenaka T
    Eur J Pharmacol; 1997 Feb; 321(2):225-30. PubMed ID: 9063692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
    Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
    Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
    Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tanaka A; Iizumi Y; Honda K
    Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():113P-117P. PubMed ID: 10629866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
    Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
    Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats.
    Tomura Y; Tahara A; Tsukada J; Yatsu T; Uchida W; Iizumi Y; Honda K
    Clin Exp Pharmacol Physiol; 1999; 26(5-6):399-403. PubMed ID: 10386228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.
    Risvanis J; Naitoh M; Johnston CI; Burrell LM
    Eur J Pharmacol; 1999 Sep; 381(1):23-30. PubMed ID: 10528130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
    Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
    Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Momose K; Taniguchi N; Suzuki T; Yatsu T; Shibasaki M
    Pharmacology; 2006; 78(2):81-90. PubMed ID: 16966841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.